BR112021019099A2 - Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios - Google Patents
Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatóriosInfo
- Publication number
- BR112021019099A2 BR112021019099A2 BR112021019099A BR112021019099A BR112021019099A2 BR 112021019099 A2 BR112021019099 A2 BR 112021019099A2 BR 112021019099 A BR112021019099 A BR 112021019099A BR 112021019099 A BR112021019099 A BR 112021019099A BR 112021019099 A2 BR112021019099 A2 BR 112021019099A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- pharmaceutical compositions
- inflammatory disorders
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1904375.1A GB201904375D0 (en) | 2019-03-29 | 2019-03-29 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2020/058061 WO2020200898A1 (en) | 2019-03-29 | 2020-03-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019099A2 true BR112021019099A2 (pt) | 2021-11-30 |
Family
ID=66442789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019099A BR112021019099A2 (pt) | 2019-03-29 | 2020-03-24 | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220296573A1 (https=) |
| EP (1) | EP3947374A1 (https=) |
| JP (1) | JP2022526553A (https=) |
| KR (1) | KR20210143905A (https=) |
| CN (1) | CN113677678A (https=) |
| AU (1) | AU2020252900A1 (https=) |
| BR (1) | BR112021019099A2 (https=) |
| CA (1) | CA3134732A1 (https=) |
| GB (1) | GB201904375D0 (https=) |
| IL (1) | IL286688A (https=) |
| MX (1) | MX2021011574A (https=) |
| PH (1) | PH12021552377A1 (https=) |
| SG (1) | SG11202110643YA (https=) |
| WO (1) | WO2020200898A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54755A (fr) * | 2019-01-18 | 2021-11-24 | Biogen Ma Inc | Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201904374D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders |
| KR20230059584A (ko) | 2021-10-26 | 2023-05-03 | 주식회사 엘지에너지솔루션 | 전극 조립체의 제조방법 |
| WO2023098857A1 (zh) * | 2021-12-03 | 2023-06-08 | 武汉人福创新药物研发中心有限公司 | Irak4抑制剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1657242A4 (en) * | 2003-08-15 | 2008-10-29 | Banyu Pharma Co Ltd | imidazopyridine |
| JPWO2005108399A1 (ja) * | 2004-05-10 | 2008-03-21 | 萬有製薬株式会社 | イミダゾピリジン化合物 |
| US9169260B2 (en) * | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| RU2675818C2 (ru) * | 2013-03-14 | 2018-12-25 | Галапаго Нв | Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств |
| EP3092226B1 (en) * | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| CN108473498B (zh) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| WO2018060174A1 (de) * | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln |
| WO2018060072A1 (de) * | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
| MA54755A (fr) * | 2019-01-18 | 2021-11-24 | Biogen Ma Inc | Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201904374D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders |
-
2019
- 2019-03-29 GB GBGB1904375.1A patent/GB201904375D0/en not_active Ceased
-
2020
- 2020-03-24 KR KR1020217035256A patent/KR20210143905A/ko not_active Withdrawn
- 2020-03-24 BR BR112021019099A patent/BR112021019099A2/pt not_active Application Discontinuation
- 2020-03-24 MX MX2021011574A patent/MX2021011574A/es unknown
- 2020-03-24 AU AU2020252900A patent/AU2020252900A1/en not_active Abandoned
- 2020-03-24 US US17/599,447 patent/US20220296573A1/en not_active Abandoned
- 2020-03-24 JP JP2021557759A patent/JP2022526553A/ja active Pending
- 2020-03-24 CA CA3134732A patent/CA3134732A1/en active Pending
- 2020-03-24 SG SG11202110643YA patent/SG11202110643YA/en unknown
- 2020-03-24 EP EP20714521.0A patent/EP3947374A1/en not_active Withdrawn
- 2020-03-24 WO PCT/EP2020/058061 patent/WO2020200898A1/en not_active Ceased
- 2020-03-24 CN CN202080026038.XA patent/CN113677678A/zh active Pending
- 2020-03-24 PH PH1/2021/552377A patent/PH12021552377A1/en unknown
-
2021
- 2021-09-26 IL IL286688A patent/IL286688A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020252900A1 (en) | 2021-11-25 |
| SG11202110643YA (en) | 2021-10-28 |
| PH12021552377A1 (en) | 2022-10-03 |
| US20220296573A1 (en) | 2022-09-22 |
| KR20210143905A (ko) | 2021-11-29 |
| MX2021011574A (es) | 2021-10-13 |
| JP2022526553A (ja) | 2022-05-25 |
| CN113677678A (zh) | 2021-11-19 |
| WO2020200898A1 (en) | 2020-10-08 |
| GB201904375D0 (en) | 2019-05-15 |
| EP3947374A1 (en) | 2022-02-09 |
| CA3134732A1 (en) | 2020-10-08 |
| IL286688A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019055A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112015020998A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| EA202091512A1 (ru) | Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы | |
| BR112022012684A2 (pt) | Compostos cíclicos e métodos de uso dos mesmos | |
| BR112017023764A2 (pt) | derivados de ciclohexano substituído por amido | |
| MX394961B (es) | Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6 | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| BR112016012734A8 (pt) | composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto | |
| BR112018067312A2 (pt) | compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| CY1121063T1 (el) | Αναστολεις της συνθασης της αλδοστερονης | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| MX386256B (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| BR112021019110A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112022001002A2 (pt) | Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença | |
| BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |